High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer
Sjoerd Rodenhuis(The Netherlands Cancer Institute), Elisabeth G.E. de Vries(Karolinska University Hospital), Harm van Tinteren(Princess Máxima Center), M. Nooij(Leiden University Medical Center), Hans Peterse(The Netherlands Cancer Institute), Emile E. Voest(University Medical Center Utrecht), John Wagstaff(Maastricht University Medical Centre), P. Hupperets(Maastricht University Medical Centre), L.V.A.M. Beex, Elisabeth M. TenVergert, Dick J. Richel(Amsterdam UMC Location University of Amsterdam), M. Bontenbal(Rotterdam University of Applied Sciences)
Cited by 262
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
|New England Journal of Medicine|2018|1.4k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
K-<i>ras</i>Oncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung
|New England Journal of Medicine|1990|811
Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy
|JNCI Journal of the National Cancer Institute|1998|768